Telix Pharmaceuticals Limited ADR (TLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | |
| Assets | ||
| Current Assets | ||
| Cash & Cash Equivalents | 468,615 | 81,879 |
| Receivables | 91,992 | 43,038 |
| Inventories | 25,164 | 11,501 |
| Other current assets | 20,206 | 18,058 |
| TOTAL | $605,977 | $154,476 |
| Non-Current Assets | ||
| PPE Net | 29,653 | 15,394 |
| Intangibles | 274,524 | 72,860 |
| Other Non-Current Assets | 90,236 | 26,989 |
| TOTAL | $394,413 | $115,243 |
| Total Assets | $1,000,390 | $269,719 |
| Liabilities | ||
| Current Liabilities | ||
| Short Term Debt | 12,528 | 641 |
| Accounts payable and accrued liabilities | 92,310 | 54,284 |
| Other current liabilities | 79,772 | 41,616 |
| TOTAL | $218,303 | $109,669 |
| Non-Current Liabilities | ||
| Long Term Debt | 364,036 | 5,454 |
| Other Non-Current Liabilities | 31,641 | 50,559 |
| TOTAL | $407,237 | $61,114 |
| Total Liabilities | $625,539 | $170,782 |
| Shareholders' Equity | ||
| Common Shares | 393,693 | 296,501 |
| Retained earnings | -140,491 | -175,179 |
| Other shareholders' equity | 104,664 | 19,359 |
| TOTAL | $374,850 | $98,937 |
| Total Liabilities And Equity | $1,000,390 | $269,719 |